Filing Flows › Amphastar Pharmaceuticals (AMPH) › Q1 2025
Amphastar Pharmaceuticals (AMPH) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Amphastar Pharmaceuticals (AMPH) reported revenue of $171M for the first quarter 2025 (Q1 2025), -0.8% from a year earlier and -9% from the quarter before. Operating margin was 21.9%, net earnings $25.3M (14.8% of revenue).
Amphastar Pharmaceuticals, Q1 2025: revenue $171M (-0.8% year over year), operating margin 21.9%, net earnings $25.3M, operating cash flow $35.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $171M | -9% | -0.8% |
| Gross profit | $85.3M | -2% | -5% |
| Operating profit | $37.3M | -17% | -22% |
| Net earnings | $25.3M | -33% | -41% |
| Operating cash flow | $35.1M | +21% | -37% |
| Free cash flow | $24.4M | +47% | -48% |
What changed
Revenue was $170.5M in Q1 2025, down 1% year over year and down 9% from the previous quarter.
Gross margin was 50.0%, down 2.4 points from a year earlier. Operating profit was $37.3M, a 21.9% margin (down 6.1 points year over year). Operating expenses grew 14% against a revenue fall of 1%. The fastest-growing cost line was Sales & marketing (+27%). Net earnings were $25.3M, down 41% year over year. The effective tax rate was 18.1%.
Operating cash flow was $35.1M (down 37% year over year), 139% of net earnings. Non-cash charges added back $13.6M of depreciation and amortization and $8.4M of share-based compensation. Working capital and other items used $12.2M. Capital expenditures of $10.7M left free cash flow of $24.4M.
Questions
What was Amphastar Pharmaceuticals' revenue in the first quarter 2025?
Amphastar Pharmaceuticals (AMPH) reported revenue of $171M for the first quarter 2025 (Q1 2025), -0.8% from a year earlier and -9% from the quarter before.
Was Amphastar Pharmaceuticals profitable in the first quarter 2025?
Operating profit was $37.3M (21.9% of revenue) and net earnings $25.3M.